Business in the Burbs

Acorda Therapeutics will continue testing MS drug

December

Acorda Therapeutics, a biotech company based in Hawthorne, said yesterday that it will conduct an additional final-phase trial of a drug for people with multiple sclerosis.

The company said it decided to continue testing the drug, Fampridine-SR, based on feedback it received from the U.S. Food and Drug Administration.

In September, the company announced that a Phase 3 trial of the drug showed that a greater proportion of people who received the drug had improved walking speed over participants who were given a placebo.

The company is hoping the drug can help 320,000 Americans with multiple sclerosis who have trouble walking.

Acorda has been working on the development of the drug since the mid-1990s. That was when Acorda acquired the rights to the medication from Elan, a pharmaceutical company in Ireland.

This entry was posted on Friday, December 8th, 2006 at 7:14 pm by Julie Moran Alterio.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.